Eli Lilly's lepodisiran met Phase 2 trial goals, significantly lowering Lp(a) levels. A Phase 3 study is enrolling to assess its impact on cardiovascular events.
Palatin's study shows co-administering bremelanotide with tirzepatide led to greater weight loss than tirzepatide alone, with further analysis ongoing.
Curious about the market action on Monday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session.
